XML 101 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated
The following tables present our segment information (in thousands):

 
Services
 
True Health (1)
 
Intersegment
Eliminations
 
Consolidated
Revenue
 
 
 
 
 
 
 
For the Year Ended December 31, 2019
 
 
 
 
 
 
 
Services:
 
 
 
 
 
 
 
Transformation Services
$
15,203

 
$
—

 
$
—

 
$
15,203

Platform and Operations Services
671,919

 
—

 
(12,481
)
 
659,438

Services Revenue
687,122

 
—

 
(12,481
)
 
674,641

True Health(1):
 
 
 
 
 
 
 
Premiums
—

 
172,722

 
(980
)
 
171,742

Total Revenue
687,122

 
172,722

 
(13,461
)
 
846,383

 
 
 
 
 
 
 
 
For the Year Ended December 31, 2018
 
 
 
 
 
 
 
Services:
 
 
 
 
 
 
 
Transformation Services
$
32,916

 
$
—

 
$
—

 
$
32,916

Platform and Operations Services
514,515

 
—

 
(14,325
)
 
500,190

Services Revenue
547,431

 
—

 
(14,325
)
 
533,106

True Health(1):
 
 
 
 
 
 
 
Premiums
—

 
94,763

 
(806
)
 
93,957

Total Revenue
547,431

 
94,763

 
(15,131
)
 
627,063

 
 
 
 
 
 
 
 
For the Year Ended December 31, 2017
 
 
 
 
 
 
 
Services:
 
 
 
 
 
 
 
Transformation Services
$
29,466

 
$
—

 
$
—

 
$
29,466

Platform and Operations Services
405,484

 
—

 
—

 
405,484

Total Revenue
434,950

 
—

 
—

 
434,950

 
 
 
 
 
 
 
 
 
Services
 
True Health (1)
 
Segments Total
 
 
For the Year Ended December 31, 2019
 
 
 
 
 
 
 
Adjusted EBITDA
$
(14,667
)
 
$
3,699

 
$
(10,968
)
 
 
 
 
 
 
 
 
 
 
For the Year Ended December 31, 2018
 
 
 
 
 
 
 
Adjusted EBITDA
$
21,310

 
$
1,915

 
$
23,225

 
 
 
 
 
 
 
 
 
 
For the Year Ended December 31, 2017
 
 
 
 
 
 
 
Adjusted EBITDA
$
(2,204
)
 
$
—

 
$
(2,204
)
 
 
(1) 
The True Health segment was created in January 2018.
Reconciliation of Adjusted EBITDA to net income (loss)
The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands):
 
For the Years Ended December 31,
 
2019
 
2018
 
2017
Net loss attributable to common shareholders of Evolent Health, Inc.
$
(301,971
)
 
$
(52,658
)
 
$
(60,665
)
Less:
 
 
 
 
 
Interest income
3,987

 
3,440

 
1,656

Interest expense
(14,534
)
 
(5,484
)
 
(3,636
)
(Provision) benefit for income taxes
21,536

 
(40
)
 
6,637

Depreciation and amortization expenses
(60,913
)
 
(44,515
)
 
(32,368
)
Goodwill impairment
(199,800
)
 
—

 
—

Loss from equity method investees
(9,465
)
 
(4,736
)
 
(1,755
)
Gain on disposal of assets
9,600

 
—

 
—

Change in fair value of contingent consideration and indemnification asset
3,997

 
4,104

 
(400
)
Other income (expense), net
(492
)
 
109

 
171

Net loss attributable to non-controlling interests
3,609

 
1,533

 
9,102

ASC 606 transition adjustments
—

 
(4,498
)
 
—

Purchase accounting adjustments
(1,915
)
 
(861
)
 
(1,467
)
Stock-based compensation expense
(15,618
)
 
(17,609
)
 
(20,437
)
Severance costs
(17,350
)
 
(2,205
)
 
—

Amortization of contract cost assets
(2,876
)
 
(2,456
)
 
—

Acquisition costs
(10,769
)
 
(2,665
)
 
(15,964
)
Adjusted EBITDA
$
(10,968
)
 
$
23,225

 
$
(2,204
)